Pharmacologic inhibition of EZH2 was demonstrated to reduce tumor growth and promote apoptosis in preclinical models of different tumor types characterized by the presence of EZH2-activating mutations [19,20] or EZH2 altered expression [21,22]. Here, EZH2 is linked to neoplasm.